{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DNX-2401",
    "query": {
      "intervention": "DNX-2401"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T15:22:59.398Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00805376",
      "title": "DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Cancer",
        "Central Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "DNX-2401",
          "type": "DRUG"
        },
        {
          "name": "Tumor Removal",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "DNAtrix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2009-02",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2018-07-16",
      "last_synced_at": "2026-09-05T15:22:59.398Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00805376"
    },
    {
      "nct_id": "NCT03896568",
      "title": "MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "IDH1 wt Allele",
        "Recurrent Anaplastic Astrocytoma",
        "Recurrent Glioblastoma",
        "Recurrent Gliosarcoma",
        "Recurrent Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Oncolytic Adenovirus Ad5-DNX-2401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-02-12",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-09-05T15:22:59.398Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896568"
    },
    {
      "nct_id": "NCT05009992",
      "title": "Combination Therapy for the Treatment of Diffuse Midline Gliomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Recurrent Diffuse Intrinsic Pontine Glioma",
        "Recurrent Diffuse Midline Glioma, H3 K27M-Mutant",
        "Recurrent WHO Grade III Glioma",
        "WHO Grade III Glioma"
      ],
      "interventions": [
        {
          "name": "ONC201",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Paxalisib",
          "type": "DRUG"
        },
        {
          "name": "DNX-2401",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "2 Years to 39 Years"
      },
      "enrollment_count": 360,
      "start_date": "2021-10-20",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-09-05T15:22:59.398Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05009992"
    },
    {
      "nct_id": "NCT02197169",
      "title": "DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma or Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Single intratumoral injection of DNX-2401",
          "type": "DRUG"
        },
        {
          "name": "Interferon-gamma",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DNAtrix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-09-11",
      "completion_date": "2018-03-15",
      "has_results": false,
      "last_update_posted_date": "2018-07-16",
      "last_synced_at": "2026-09-05T15:22:59.398Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197169"
    },
    {
      "nct_id": "NCT07444606",
      "title": "Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "DNX-2401",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-08-31",
      "completion_date": "2029-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-05T15:22:59.398Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444606"
    },
    {
      "nct_id": "NCT02798406",
      "title": "Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Cancer",
        "Brain Neoplasm",
        "Glioma",
        "Glioblastoma",
        "Gliosarcoma",
        "Malignant Brain Tumor",
        "Neoplasm, Neuroepithelial",
        "Neuroectodermal Tumors",
        "Neoplasm by Histologic Type",
        "Neoplasm, Nerve Tissue",
        "Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "DNX-2401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DNAtrix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2016-10-06",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-09-05T15:22:59.398Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02798406"
    }
  ]
}